Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log-in |  Register |  Search

Back to the forum  Query: 2017-12-14 01:44 CET (UTC+1h)
 

Clinical significance of Tmax [Regulatives / Guidelines]

posted by M.tareq - 2017-10-12 07:53  - Posting: # 17890
Views: 771

Dear all ,

I have a question about Tmax from clinical perspective.

According to EMA guidance:
"A statistical evaluation of tmax is not required. However, if rapid release is claimed to be clinically relevant and of importance for onset of action or is related to adverse events, there should be no apparent difference in median tmax and its variability between test and reference product."

If a fast disintegrating tab has a tmax earlier than the conventional release, does it prove that it has an earlier onset of action?

Thanks in advance and Best regards

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum | Admin contact
17,558 Posts in 3,759 Threads, 1,090 registered users;
32 users online (0 registered, 32 guests).

Power: That which is wielded by the priesthood of
clinical trials, the statisticians, and a stick which they use
to beta their colleagues.    Stephen Senn

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
XHTML/CSS RSS Feed